AkiMed™
Breast reconstruction post-lumpectomy
Key Facts
About Akira Science
Akira Science is an early-stage biotech firm based in Stockholm, founded in 2021, that is merging AI-driven discovery with advanced tissue engineering. The company's lead program, AkiMed™, is a bioresorbable breast implant aimed at addressing the significant unmet need in breast cancer reconstruction, offering a more natural and accessible alternative to current complex procedures. While positioned in the tissue engineering sector, their core description emphasizes an AI platform for therapeutic acceleration, indicating a dual focus on platform technology and product development. The company appears to be in a pre-clinical, pre-revenue stage, building its foundational technology and initial product candidate.
View full company profile